AgroAmerica Presents Its 2022 Sustainability Report: A Future Built to Last
18.7.2023 17:12:00 EEST | Business Wire | Press release
AgroAmerica presented its ninth Sustainability Report. This report provides an updated overview of the performance of the company’s banana division and the achievements made in 2022 through its Corporate Sustainability Strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230717281841/en/
AgroAmerica's sustainability report details the structure, governance, strategy, and management of the company, with a specific focus on the material issues identified. Over the past year, AgroAmerica has worked on environmental, social, and governance topics that are relevant to the business. (Photo: Business Wire)
"We are pleased to announce that the year 2022 marks the final chapter of our current strategy, as well as the starting point of a significant transformation. In this process, our strong foundation in sustainability will drive a new robust integrated strategy that will shape our path in 2023-24. This exciting step will lead us to continuous improvement and a more sustainable future," explained Fernando Bolaños, CEO of AgroAmerica.
Using a regenerative approach, the company undertakes actions aimed at promoting soil health, resource conservation, biodiversity preservation, and the reduction of carbon emissions. As part of this strategy, AgroAmerica has initiated a project, unique in the region, that protects bees and other pollinators in forest conservation areas located in our operations.
Some of the highlighted achievements included in this report:
- The installation of a macro sanctuary to house and protect more than 30,000 native bees and pollinators.
- Receiving the "2022 Conservation Leadership Award" from the RSPO Excellence Awards to the Mayan Biosphere conservation project.
- Receiving the "Grand Prize in Business Sustainability" from the American Chamber of Commerce for our "Mangrove Ecosystem Restoration Project" on the Pacific Coast of Guatemala.
- Obtaining the “RSPO certification” in our operations in Panama, meaning that all the operations of the tropical oil division in AgroAmerica are now certified.
- The generation of over 12,000 direct and indirect jobs that promote gender equality and development opportunities for our employees, their families and our neighboring communities.
- Contributing to 11 of the United Nations’ Sustainable Development Goals.
- Holding 11 international certifications related to good practices, sustainable operations, and food quality and safety.
- The conservation of more than 970 hectares of forests in areas within our company’s operations.
"We are a world-class corporation that adapts to global market challenges to exceed environmental, governance and social expectations and offer high-value-added products to the world," stated Javier Aguirre, Corporate Director.
This report shows our path forward with a renewed focus on sustainability, and reaffirms our company's commitment to the environment, society, and governance in the production of high-quality sustainable food.
See full report here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230717281841/en/
Contact information
Susana Perez
Communications and Public Relations Coordinator
sperez@agroamerica.com
(+502) 5554-8774
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom